|Videos|June 1, 2023
Evaluating Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer by MRR Status
Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
FDA Grants Priority Review to Zanubrutinib Regimen in Frontline MCL
4
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
5